News | August 22, 2024
Wanbury bags safety awards for its API manufacturing site in Patalganga
These accolades highlight our unwavering commitment to maintaining the highest safety standards
These accolades highlight our unwavering commitment to maintaining the highest safety standards
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The company has received Form 483 with three observations
The inspection closed with the facility receiving an inspection classification of NAI
The company will submit its comprehensive response on these observations to the US FDA
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
